Tonix Pharmaceuticals Holding Corp.

509 Madison Avenue, Suite 1608

New York, New York 10022


November 14, 2019


United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re:Tonix Pharmaceuticals Holding Corp.

Registration Statement on Form S-1 (File No. 333-234263)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 4 p.m, Eastern Standard Time, on November 14, 2019, or as soon as practicable thereafter.


Please call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 to confirm the effectiveness of the Registration Statement or with any questions.

[Signature page follows.]


U.S. Securities and Exchange Commission

November 14, 2019

Page 2

  Very truly yours,
  By:  /s/ Bradley Saenger
  Name: Bradley Saenger
  Title: Chief Financial Officer